Effectiveness and Safety of Switching to Ravulizumab From Eculizumab in Kidney Transplant Recipients With Atypical Hemolytic Uremic Syndrome: A Global aHUS Registry Analysis
Clinical Transplantation · 2025
DOI: 10.1111/ctr.70278 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Transplantation, 2025. Verfasst von Anja Gaeckler und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, University Hospital Essen, University Duisburg-Essen, Essen, Germany. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Atypical Hemolytic Uremic Syndrome, Kidney Transplantation, Complement Inactivating Agents. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alexion, AstraZeneca Rare Disease, Boston, MA, USA.
Abstract (Originalsprache)
Introduction
Atypical hemolytic uremic syndrome (aHUS) is a disease of complement dysregulation that may lead to kidney failure. Ravulizumab and eculizumab are complement C5 inhibitors approved for the treatment of aHUS. This study assessed the real‐world effectiveness and safety of switching to ravulizumab from eculizumab in kidney transplant recipients with aHUS.
Methods
The Global aHUS Registry is a multicenter study enrolling patients with aHUS since 2012. Effectiveness and safety outcomes were assessed in kidney transplant recipients with aHUS who switched to ravulizumab from eculizumab up to September 2, 2024.
Results
Overall, 38 patients received a kidney transplant before ravulizumab initiation; 27 patients with ≥3 months of ravulizumab treatment were included in the patient characteristics and effectiveness analyses. Median (range) time on eculizumab and ravulizumab treatment was 66.1 (3.7, 158.3) and 24.1 (4.2, 49.3) months, respectively ( n = 27); time from last kidney transplantation to ravulizumab initiation was 65.9 (3.7, 184.0) months. Following ravulizumab initiation, laboratory parameters remained stable, and no kidney transplant rejections/graft failures were reported. In the safety analysis ( n = 38), 23 adverse events were reported in 19 patients (50.0%) at or after ravulizumab initiation, and none were considered treatment‐related. No new events of thrombotic microangiopathy or kidney impairment and no meningococcal infections or deaths were reported.
Conclusion
This analysis from the Global aHUS Registry provides real‐world evidence to demonstrate that the transition to ravulizumab from eculizumab in kidney transplant recipients with aHUS is successful, with stable graft function with no treatment‐related safety concerns. Trial Registration ClinicalTrials.gov identifier: NCT01522183
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
- Global Medical Affairs, Alexion, AstraZeneca Rare Disease, Boston, Massachusetts, USA.
- Department of Nephrology, Odense University Hospital, Odense, Denmark.
- aHUS Canada, Brampton, Ontario, Canada.
- Division of Pediatric Nephrology, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
- Department of Kidney and Transplant Services, The University of Queensland and Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Förderung
- Alexion, AstraZeneca Rare Disease, Boston, MA, USA
Zitieren
APA
Gaeckler, A., Al-Dakkak, I., Saval, N., Dieperink, H. H., Eygenraam, M., Greenbaum, L. A., Isbel, N., & Walle, J. V. (2025). Effectiveness and Safety of Switching to Ravulizumab From Eculizumab in Kidney Transplant Recipients With Atypical Hemolytic Uremic Syndrome: A Global aHUS Registry Analysis. Clinical Transplantation. https://doi.org/10.1111/ctr.70278
Vancouver
Gaeckler A, Al-Dakkak I, Saval N, Dieperink HH, Eygenraam M, Greenbaum LA, et al. Effectiveness and Safety of Switching to Ravulizumab From Eculizumab in Kidney Transplant Recipients With Atypical Hemolytic Uremic Syndrome: A Global aHUS Registry Analysis. Clinical Transplantation. 2025. doi:10.1111/ctr.70278
BibTeX
@article{Gaeckler2025,
author = {Gaeckler, Anja and Al-Dakkak, Imad and Saval, Nuria and Dieperink, Hans Herman and Eygenraam, Margriet and Greenbaum, Larry A and Isbel, Nicole and Walle, Johan Vande},
title = {Effectiveness and Safety of Switching to Ravulizumab From Eculizumab in Kidney Transplant Recipients With Atypical Hemolytic Uremic Syndrome: A Global aHUS Registry Analysis},
journal = {Clinical Transplantation},
year = {2025},
doi = {10.1111/ctr.70278}
}
EUVIMED